A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Kerato… (NCT03285490) | Clinical Trial Compass
CompletedPhase 3
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
United States351 participantsStarted 2017-09-15
Plain-language summary
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females greater than or equal to (\>=) 18 years old.
✓. A defined area on the face or scalp contains 4 to 8 clinically typical, visible, and discrete AK lesions.
✓. Participants who in the judgment of the Investigator, were in good general health.
✓. Females were postmenopausal (greater than \[\>\] 45 years of age with at least 12 months of amenorrhea), surgically sterile (by hysterectomy, bilateral oophorectomy, or tubal ligation); or, if of childbearing potential, were using highly effective contraception for at least 30 days or 1 menstrual cycle, whichever was longer, prior to study treatment and agreed to continue to use highly effective contraception for at least 30 days following their last dose of study treatment. Highly effective contraception includes oral hormonal contraceptives, hormonal contraceptive implant, injection or patch, intrauterine device or complete abstinence from sexual intercourse.
✓. Sexually active males who had not had a vasectomy, and whose partner was reproductively capable, must had agreed to use barrier contraception from Screening through 90 days after their last dose of study treatment.
✓. All participants must had agreed not to donate sperm or eggs or attempt conception from Screening through 90 days following their last dose of study treatment.
✓. Willing to avoid excessive sun or ultraviolet exposure.
✓. Able to comprehend and were willing to sign the informed consent form (ICF).
Exclusion criteria
✕. Clinically atypical and/or rapidly changing AK lesions on the treatment area.
What they're measuring
1
Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions
✕. Been previously treated with KX2-391 Ointment.
✕. Anticipated need for in-patient hospitalization or in-patient surgery from Day 1 to Day 57.
✕. Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the treatment area or within 2 cm of the treatment area, within 8 weeks prior to the Screening visit.
✕. Use of the following therapies and/or medications within 2 weeks prior to the Screening visit:
✕. Use of the following therapies and/or medications within 4 weeks prior to the Screening visit:
✕. Use of systemic retinoids (eg, isotretinoin, acitretin, bexarotene) within 6 months prior to the Screening visit.